Trial Title:

UNISoN: anzUp Nivo -> Ipi + Nivo Sequential Non-clear cell

Proposed phase II sequential cohort trial of single agent Nivolumab, then combination Ipilimumab + Nivolumab in Metastatic or unresectable non-clear cell renal cell carcinoma

Trial Acronym:


Protocol Number:

ANZUP 1602

Trial Design:

Single-arm, multicentre, phase 2 trial

ANZ Study Chairs:

Dr Craig Gedye

ANZ Coordinating Centre:

Centre for Biostatistics and Clinical Trials

Trial Coordinator:


Trial Email:


Recruitment Aim: 
85 participants (Part 1) RECRUITMENT CLOSED
48 participants (Part 2)

Patient Population:

Adults with m-n-ccRCC. Key eligibility criteria include target lesion(s) according to RECIST 1.1, good performance status (ECOG 0-1), no history of significant autoimmune disease, tumour sample available (previously resected or fresh biopsy) and no previous treatment with immunotherapy.  


1st stage, nivolumab 240mg IV q2w, until prohibitive toxicity, death, disease progression or 12 months of treatment. If disease progresses on nivolumab alone, and patient PS remains good (0-1), patient may enter 2nd stage; nivolumab 240mg IV q2w + ipilimumab 1mg/kg q3w x 4 cycles, then continue nivolumab until prohibitive toxicity, death, disease progression or 12 months total nivolumab treatment. Treatment beyond 12 months or beyond late progression with discussion with Study PI and sponsor.

Primary Outcome:

1. Objective tumour response rate (OTRR = CR or PR, RECIST 1.1) of nivolumab in m-n-ccRCC

2. Objective tumour response rate (OTRR = CR or PR, RECIST 1.1) of ipilimumab + nivolumab in patients with m-n-ccRCC refractory to nivolumab alone

Secondary Outcomes:

3. Progression-free survival at 6 months (PFS6m, proportion alive and progression-free at 6 months according to RECIST 1.1)
4. OTRR and disease control rate (CR, PR, or SD at 6 months) according to irRC.
5. Frequency and severity of adverse events (CTCAE v4.03), particularly selected immune-related adverse events (IRAE)
6. Frequency of treatment modifications and discontinuation due to toxicity


Closed to recruitment

Sites Recruiting:

  • Border Medical Oncology
  • Calvary Mater Newcastle
  • Campbelltown Hospital
  • Chris O'Brien Lifehouse
  • Northern Cancer Institute
  • Port Macquarie Base Hospital
  • Prince of Wales Hospital
  • St George Hospital
  • St Vincent's Hospital
  • Tamworth Hospital
  • Westmead Hospital
  • Ballarat Oncology & Haematology Service
  • Eastern Health
  • Monash Health - Clayton
  • Adelaide Cancer Centre/Ashford Cancer Centre Research
  • Flinders Medical Centre
  • Royal Brisbane and Women's Hospital
  • Sunshine Coast University Hospital
  • Fiona Stanley Hospital
Further Information: Click here
© ANZUP 2021. All rights reserved.